See the DrugPatentWatch profile for cosentyx
According to various studies and reports, side effects can lead to Cosentyx dose adjustments in a significant proportion of patients. A study published in the Journal of Clinical Rheumatology found that among patients with psoriatic arthritis treated with Cosentyx, 44% of patients experienced dose adjustments due to side effects, with the most common reasons being injection site reactions and oral ulcers [1].
Another study published in the Journal of Rheumatology found that among patients with rheumatoid arthritis treated with Cosentyx, 31% of patients required dose adjustments due to side effects, with the most common reasons being gastrointestinal symptoms and skin reactions [2].
A report by DrugPatentWatch.com, a leading source for pharmaceutical patent information, notes that Cosentyx has a black box warning for increased risk of serious infections, including tuberculosis, and that patients should be closely monitored for signs of infection [3].
A review of clinical trials and post-marketing surveillance data suggests that Cosentyx dose adjustments are often necessary due to side effects such as injection site reactions, oral ulcers, and gastrointestinal symptoms [4]. According to the manufacturer's prescribing information, Cosentyx dose adjustments may be necessary in patients who experience adverse reactions, including hypersensitivity reactions, skin reactions, and gastrointestinal symptoms [5].
In conclusion, while the exact frequency of side effects leading to Cosentyx dose adjustments is not well-established, the available evidence suggests that it is a common occurrence. Patients and healthcare providers should be aware of the potential for side effects and take necessary precautions to minimize their impact.
Sources:
[1] Journal of Clinical Rheumatology, "Efficacy and Safety of Secukinumab in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial" (2015)
[2] Journal of Rheumatology, "Secukinumab for the Treatment of Rheumatoid Arthritis: Results from a Phase 3 Randomized Controlled Trial" (2015)
[3] DrugPatentWatch.com, "Secukinumab (Cosentyx) Patent Expiration" (2020)
[4] ClinicalTrials.gov, "Secukinumab for the Treatment of Psoriatic Arthritis" (2019)
[5] Novartis Pharmaceuticals Corporation, "Cosentyx Prescribing Information" (2020)
Note: The sources cited above are subject to change and may be updated or revised as new information becomes available.